Retrospective Cohort Study
Copyright ©The Author(s) 2019.
World J Gastroenterol. Mar 14, 2019; 25(10): 1238-1247
Published online Mar 14, 2019. doi: 10.3748/wjg.v25.i10.1238
Table 1 Demographic and clinicopathologic characteristics n (%)
Overall (n = 1303)Recurrence (107)No recurrence (1196)OR (95%CI)P-value
Gender
Male681 (52.3)65 (60.7)616 (51.5)
Female622 (47.7)42 (39.3)580 (48.5)0.686 (0.458, 1.028)0.067
Age (yr)
Mean (SD)55.77 (13.696)55.76 (0.390)55.83 (1.538)1.000 (0.986, 1.015)0.276
Tumor location
Gastric873 (67.0)38 (35.5)835 (69.8)
Non-gastric430 (33.0)69 (64.5)361 (30.2)4.200 (2.774, 6.359)< 0.05
Follow-up period (mo)
Mean (SD)64.91 (35.793)75.36 (4.608)63.98 (0.995)1.008 (1.003, 1.013)< 0.05
Tumor size
Mean (SD)5.14 (4.862)9.01 (0.663)4.80 (0.130)1.128 (1.092, 1.165)< 0.05
≤ 5 cm775 (59.5)28 (26.2)747 (62.5)
> 5 cm528 (40.5)79 (73.8)449 (37.5)4.694 (3.003, 7.337)< 0.05
Mitotic index
≤ 5/50 HPFs877 (67.3)44 (41.1)833 (69.6)
> 5/50 HPFs426 (32.7)63 (58.9)363 (30.4)3.286 (2.193, 4.923)< 0.05
Tumor rupture
Yes34 (2.6)27 (25.2)7 (0.6)57.327 (24.220, 135.685)
No1269 (97.4)80 (74.8)1189 (99.4)< 0.05
Modified NIH
Very low risk347 (26.6)14 (13.10)333 (27.80)0.182 (0.101, 0.329)< 0.05
Low risk394 (30.2)10 (9.30)384 (32.10)0.113 (0.057, 0.222)< 0.05
Intermediate risk162 (12.4)8 (7.50)154 (12.90)0.225 (0.106, 0.478)< 0.05
High risk400 (30.7)75 (70.10)325 (27.20)
AFIP criteria
Very low risk619 (47.5)15 (14.00)604 (50.50)0.081 (0.045, 0.146)< 0.05
Low risk250 (19.2)16 (15.00)234 (19.60)0.224 (0.125, 0.401)< 0.05
Intermediate risk173 (13.3)15 (14.00)158 (13.20)0.311 (0.170, 0.568)< 0.05
High risk261 (20.0)61 (57.00)200 (16.70)
Table 2 Pairwise comparisons of receiver operating characteristic curves
Difference (95%CI)P-value
AFIP-MAP0.34850.7275
AFIP-MSKCC_2 yr-0.29330.7693
AFIP-MSKCC_5 yr0.55970.5757
AFIP-Modified NIH4.2594< 0.05
MAP-MSKCC_2 yr-0.42960.6675
MAP-MSKCC_5 yr0.35590.7219
MAP-Modified NIH1.72020.0854
MSKCC_2 yr-MSKCC_5 yr0.78950.4298
MSKCC_2 yr-Modified NIH1.28290.1995
MSKCC_5 yr-Modified NIH0.57110.5679